Cargando…

Imiglucerase in the treatment of Gaucher disease: a history and perspective

The scientific and therapeutic development of imiglucerase (Cerezyme(®)) by the Genzyme Corporation is a paradigm case for a critical examination of current trends in biotechnology. In this article the authors argue that contemporary interest in treatments for rare diseases by major pharmaceutical c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deegan, Patrick B, Cox, Timothy M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340106/ https://www.ncbi.nlm.nih.gov/pubmed/22563238 http://dx.doi.org/10.2147/DDDT.S14395

Ejemplares similares

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
por: Schiffmann, Raphael, et al.
Publicado: (2022)

Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
por: Doneda, Divair, et al.
Publicado: (2013)

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
por: Serratrice, Christine, et al.
Publicado: (2016)

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
por: Xu, You-Hai, et al.
Publicado: (2010)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2012)

Achievement of Therapeutic Goals with Low-Dose Imiglucerase in Gaucher Disease: A Single-Center Experience
por: Tukan, Irina, et al.
Publicado: (2013)

Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series
por: Serratrice, Christine, et al.
Publicado: (2015)

Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2013)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3
por: Machaczka, Maciej, et al.
Publicado: (2014)

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1
por: Stirnemann, Jérôme, et al.
Publicado: (2015)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
por: Sidhu, Karamjot, et al.
Publicado: (2020)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Gba1 Mutant Mouse Model Treated with Velaglucerase alfa or Imiglucerase
por: Dasgupta, Nupur, et al.
Publicado: (2013)

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
por: Sims, KB, et al.
Publicado: (2008)

Gaucher disease: clinical profile and therapeutic developments
por: Cox, Timothy M
Publicado: (2010)

The motor and cognitive features of Parkinson’s disease in patients with concurrent Gaucher disease over 2 years: a case series
por: Collins, Lucy M., et al.
Publicado: (2018)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

In-depth phenotyping for clinical stratification of Gaucher disease
por: D’Amore, Simona, et al.
Publicado: (2021)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Rethinking fatigue in Gaucher disease
por: Zion, Y. Chen, et al.
Publicado: (2016)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher disease protects against tuberculosis
por: Fan, Jingwen, et al.
Publicado: (2023)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
por: Stirnemann, Jérôme, et al.
Publicado: (2017)

Animal Models for the Study of Gaucher Disease
por: Cabasso, Or, et al.
Publicado: (2023)

Gaucher’s Disease
Publicado: (1916)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
por: Bennett, Lunawati L, et al.
Publicado: (2015)

Gaucher disease and the synucleinopathies: refining the relationship
por: Campbell, Tessa N, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_aq2sp99ev25gbjrl3iv135qt8q